The convergence of synthetic biology and artificial intelligence is widening the gap between technological advancement and existing regulatory frameworks — a phenomenon known as regulatory lag. As global competition intensifies to capture a synthetic biology market projected to reach approximately $70 billion by 2030, nations are responding to this challenge through markedly different approaches. This study applies a comparative legal methodology, drawing on co-evolutionary theory and the Law 1.0/2.0/3.0 framework, to analyze the regulatory responses of the United States, United Kingdom, Japan, and South Korea. The analysis reveals that national differences stem less from institutional design choices than from the triggers that initiate regulatory change, yielding four distinct co-evolutionary pathways. In the United States, a shift in the judicial environment prompted regulatory adaptation; in the United Kingdom, a political transition created the conditions for legislative reform; and in Japan, administrative reinterpretation of existing rules enabled regulatory adjustment. South Korea represents a fundamentally different case. By enacting the world’s first standalone synthetic biology legislation prior to full technological maturation, Korea has pursued a top-down co-evolutionary model in which institutional design precedes and shapes the trajectory of technological development. Three conclusions emerge from this analysis: there is no single optimal co-evolutionary pathway; institutional flexibility determines the sustainability of co-evolution; and co-evolution can itself be an object of proactive design. For Korea's preemptive model to prove effective, it requires a sufficient scientific foundation, institutional flexibility, and coherence with existing regulatory frameworks — conditions that offer a reference point for other nations confronting similar governance challenges.

Antimicrobial resistance (AMR) in marine environments remains difficult to assess under standard antimicrobial susceptibility testing conditions, which may not adequately reflect the physiological requirements of marine-derived bacteria. In this study, we applied NaCl-supplemented susceptibility testing conditions to bacterial isolates recovered from coastal environments and marine organism guts to evaluate their practical applicability and limitations. A total of 927 isolates were obtained from lagoon, seawater, soil, and gut samples of abalone, crab, eel, halibut, and salmon. Of these, 365 isolates grew on standard Mueller–Hinton (MH) medium, whereas 562 isolates were not evaluable under standard MH conditions. Taxonomic analysis showed that the isolate collection was dominated by Proteobacteria and Firmicutes, with Vibrio as the most abundant genus. Disk diffusion assays of the 365 MH-grown isolates revealed differences in screening-level reduced susceptibility profiles among sample groups, and putative multidrug resistance was frequently observed in Vibrio isolates from abalone and seawater. For isolates not evaluable under standard MH conditions, minimum inhibitory concentration (MIC) analysis was performed using 2% NaCl-supplemented MH broth. Under these conditions, 115 isolates showed stable growth and distinct antibiotic-dependent MIC profiles. Chloramphenicol and tetracycline inhibited most isolates at relatively low concentrations, whereas reduced susceptibility to penicillin was relatively high in isolates from seawater, abalone, and eel. Overall, these findings suggest that standard MH conditions alone may be insufficient for evaluating antibiotic responses in marine- and brackish-origin bacteria, and that 2% NaCl-supplemented MH broth can serve as a practical supplementary condition for selected marine-derived isolates.

Fecal microbiota transplantation (FMT) has been successfully applied on clinical aspects, but its clinical outcomes remain unpredictable due to inconsistent donor screening protocols across hospitals, institutions, and countries. Hence, a retrospective analysis of metagenomic data from published studies on FMT donors via a unified bioinformatics workflow might contribute to the understanding of the safety considerations for donor screening and the fecal microbial profiles of qualified donors. In this study, we reanalyzed metagenomic data of 475 screened donor fecal samples from 24 studies spanning China, the USA, Canada, New Zealand, and the Netherlands. The genomic safety risks were evaluated by profiling antibiotic resistance genes (ARGs) and virulence factors (VFs), the results of which showed that no major toxin-associated virulence genes, such as Shiga toxin, Shiga-like toxin, or botulinum neurotoxin (BoNTs) genes harbored in the detected Escherichia coli, Clostridium butyricum, and Streptococcus pneumoniae, but several high-risk ARGs remained insufficiently addressed. The distribution of ARG-harboring bacteria in eligible FMT donors was country-specific. The alpha-diversity and microbial community structure were comparable between donor fecal samples from China and the USA. Interestingly, the core microbiome in fecal samples from Canada, the Netherlands, and New Zealand formed a single guild, while that from China and the USA formed two guilds, with predominantly positive intra-guild and negative inter-guild correlations, indicating that the co-abundance patterns of the core microbiome were conserved among certain countries. Furthermore, an exploratory retrospective classifier was developed based on core microbiome profiles to distinguish eligible FMT donors from general healthy individuals. These results provide evidence for integrating metagenomic sequencing into future FMT donor screening strategies.

Human adenovirus type 55 (HAdV-55) is an emerging respiratory pathogen associated with severe pneumonia, for which no licensed vaccines are currently available. The lack of physiologically relevant small-animal models has limited preclinical evaluation of vaccine candidates. In this study, we generated a transgenic mouse model co-expressing human CD46 and desmoglein-2 (DSG-2), key entry receptors for HAdV-55, and evaluated its utility for vaccine efficacy testing. A bicistronic expression system enabling simultaneous expression of CD46 and DSG-2 was constructed and functionally validated in vitro, demonstrating enhanced susceptibility to HAdV-55 infection. The transgenic mice exhibited dose-dependent weight loss, robust viral replication in lung tissues, and characteristic histopathological changes following intranasal challenge, recapitulating key features of human adenoviral pneumonia. Using this model, we assessed the immunogenicity and protective efficacy of an inactivated HAdV-55 (iHAdV-55) vaccine formulated with alum. Vaccination induced strong HAdV-55-specific IgG and neutralizing antibody responses, which increased over time following prime–boost immunization. Upon viral challenge, vaccinated mice showed significantly reduced weight loss and accelerated recovery compared to controls. Viral load analysis demonstrated effective control of viral replication and clearance in vaccinated animals. Collectively, these findings establish the CD46/DSG-2 transgenic mouse as a physiologically relevant and translationally valuable model for HAdV-55 infection and demonstrate that iHAdV-55 vaccination confers robust humoral immunity and protective efficacy. This platform provides a critical tool for the development and preclinical evaluation of adenovirus-targeted vaccines and therapeutics.

Coronaviruses cause a wide range of diseases, ranging from the common cold to severe illnesses such as COVID-19. Although vaccines and therapeutics against COVID-19 have been developed, recent reports have documented the emergence of viral variants with reduced susceptibility to these interventions, suggesting that coronaviruses may continue to circulate persistently, similar to influenza viruses. Cirsium japonicum var. spinossimum Kitam. (hereafter referred to as C. japonicum) has traditionally been used to treat various medical conditions, including inflammatory diseases; however, its antiviral properties remain poorly understood. In this study, we demonstrated that C. japonicum extract inhibited human coronavirus replication and alleviated virus-induced cytotoxicity. Analysis of the chemical constituents of the extract identified cirsimaritin, a major flavonoid present in C. japonicum, as an active compound with antiviral activity against human coronavirus. The antiviral effects of both C. japonicum extract and cirsimaritin were further confirmed using scanning electron microscopy and a three-dimensional spheroid model. Finally, we demonstrated that C. japonicum extract and cirsimaritin inhibited coronavirus papain-like protease activity. These findings suggest that C. japonicum extract and cirsimaritin have potential as therapeutic candidates for coronavirus-associated diseases.

Microbiome studies require multiple analytical steps after initial sequence processing. These steps commonly include data harmonization, preprocessing, taxonomic profiling, diversity analysis, differential abundance testing, predictive modeling, network inference, and preparation of publication-ready outputs. Although robust packages are available for many of these tasks, routine use often depends on command-line workflows, repeated data reformatting, and method-specific scripting. These requirements can limit accessibility for experimental researchers and complicate consistent analysis across interdisciplinary teams. We developed SimpleMicrobiome, a web-based R Shiny platform that integrates established microbiome analysis methods into a single interactive downstream workflow. The application accepts standard abundance, taxonomy, and metadata tables, supports interactive preprocessing and sample filtering, and provides modules for taxa profile visualization, alpha and beta diversity analysis, ANCOM-BC2 and MaAsLin2 differential abundance testing, Random Forest modeling with SHAP-based interpretation, microbial association network inference using SparCC and SPIEC-EASI through NetCoMi, correlation heatmaps, and dbRDA/CAP-style association biplots. The platform is implemented as a modular Shiny application so that preprocessing choices are propagated across downstream analyses, results can be exported as figures and tables, and the same application can be run through the public server, source-code installation, or a Docker image.

SimpleMicrobiome consolidates major downstream microbiome analysis tasks in an accessible browser-based environment while retaining links to established analytical frameworks. The platform may reduce technical barriers for non-programming users, improve consistency across exploratory and reporting-oriented analyses, and support collaborative microbiome research. The public application is available at https://simplemicrobiome.mglab.org, the source code is available at https://github.com/yjcho2252/SimpleMicrobiome, and a Docker image for local deployment is available at https://hub.docker.com/r/mglab2252/simplemicrobiome.